European generics group demands action on EU calls for greater pharma competition

Medicines for Europe, the trade group representing the continent’s generics and biosimilars industry, has said it will work with health ministers to ensure swift implementation of calls for greater pharma competition which were made in the Council of the European Union this week.

The Council was discussing the current state of the sector as it wants to improve patient access to essential medicines, and concluded that there was a need to strengthen the balance within the pharmaceutical system in the European Union and its member states.

These conclusions underline the importance of the timely availability of generics and biosimilar medicines to improve patient access to therapy and to ensure the sustainability of national health systems, according to Medicines for Europe.